Catholic University of the Sacred Heart
unicatt.itTotal trials
234
Active
23
Phase 3
13
Total enrollment
76,794
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Polygenic Risk Score | — | — | — | — | — | 1 | |
| Pharmacogenetic profiles | — | — | — | — | — | 1 |
Next readouts
- 2027-02
Top conditions
- Polycystic Ovary Syndrome11
- Obesity9
- Developmental Dyslexia5
- Morbid Obesity4
- Oral Lichen Planus4
- Pelvic Organ Prolapse3
- Diabetes Mellitus3
- Ovarian Cancer3
Frequently asked questions about Catholic University of the Sacred Heart
- How many clinical trials does Catholic University of the Sacred Heart have on ClinicalTrials.gov?
- Catholic University of the Sacred Heart is listed as the lead sponsor on 234 clinical trials in ClinicalTrials.gov, 23 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Catholic University of the Sacred Heart's trials are in Phase 3?
- 13 of Catholic University of the Sacred Heart's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Catholic University of the Sacred Heart focus on?
- Catholic University of the Sacred Heart's most-studied conditions on ClinicalTrials.gov are Polycystic Ovary Syndrome, Obesity, Developmental Dyslexia, Morbid Obesity, Oral Lichen Planus.
- When are Catholic University of the Sacred Heart's next clinical trial readouts?
- Catholic University of the Sacred Heart has 1 upcoming primary-completion readout tracked here; the soonest is “Evaluation of Polygenic Risk Score for Epithelial OVarian cancEr Risk Prediction: the PROVE Study”, expected around 2027-02.